Evaluation of Mdh1 Protein as an Antigenic Candidate for a Vaccine against Candidiasis
Access this Article
Search this Article
<I>Candida albicans</I> malate dehydrogenase (Mdh1p) has been screened by previous proteome studies as a candidate for a vaccine against candidiasis. In this study, recombinant Mdh1 protein with a His-tag was produced in <I>Escherichia coli</I> and evaluated as an immunogenic protein against candidiasis. Mdh1p was administrated to mice by two methods subcutaneous injection and intranasal administration before challenging them with a lethal dose of <I>C. albicans</I>. After vaccination of Mdh1p, antibody responses were observed. To evaluate the vaccination effect of Mdh1p, survival tests were performed after 35 d. Although all control mice died within 24 d or 25 d, 100% and 80% of mice survived with subcutaneous and intranasal administration, respectively. Therefore, our results indicate that, among <I>C. albicans</I> antigens examined thus far, Mdh1p is currently the most effective antigen for use as a vaccine for <I>C. albicans</I>.
- Biocontrol Science
Biocontrol Science 19(1), 51-55, 2014
The Society for Antibacterial and Antifungal Agents, Japan